<DOC>
	<DOC>NCT00245765</DOC>
	<brief_summary>A study to assess the safety and efficacy of 2 different doses of CDP870 versus placebo, administered during 12 weeks, to patients suffering from moderate to severe chronic plaque psoriasis, extended by a 12 to 24 week follow-up.</brief_summary>
	<brief_title>Efficacy Study of CDP870 in Subjects With Chronic Plaque Psoriasis Who Are Candidate for Systemic Therapy and/or Phototherapy/Photochemotherapy</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Certolizumab Pegol</mesh_term>
	<criteria>men and women &gt; 18 years; Chronic plaque psoriasis stable for at least 3 months and moderate to severe for at least 6 months; PASI ≥ 12 and BSA ≥ 10%; Candidates for systemic psoriasis therapy and/or phototherapy and/or photochemotherapy; Erythrodermic, guttate, palmar or plantar, generalized pustular form of psoriasis; A history of chronic infection, recent serious or lifethreatening infection (within six months, including herpes zoster), or any current sign or symptom that may indicate an infection (e.g. fever, cough); White blood cell counts less than 4000/mm3 or more than 20000/mm3; Suspected or diagnosed demyelinating disease of the central nervous system (e.g. multiple sclerosis or optic neuritis); Systemic Lupus; Non respect of adequate wash out periods for treatments that might have an impact on the disease Any associated disease that could be impacted by the study treatment intake Any other condition, which in the Investigator's judgment would make the subject unsuitable for inclusion in the study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2009</verification_date>
	<keyword>chronic plaque psoriasis, anti TNFα</keyword>
	<keyword>CDP870, Cimzia</keyword>
</DOC>